Table 1.

Ongoing and completed clinical trials with Hsp inhibitors in lung cancer patients

Inhibitor	clinicaltrials.gov number	Treatment	Phase	Patients group
Hsp90
AUY922	NCT01259089 NCT01784640 NCT02276027	AUY922 monotherapy AUY922+erlotinib AUY922monotherapy	PhaseI/II Phase1 Phase II	Stage IIIB-IV NSCLC patients Previously treated stage IV NSCLC patients Chinese patients with advanced NSCLC
Ganetespib (STA-9090)	NCT01579994 NCT01590160	Ganetespib + crizotinib Ganetespib +platinum	Phase I Phase I/II	Patients with ALK positive lung cancer Patients with malignant pleural mesothelioma (MESO-02)
Onalespib	NCT02535338	Onalespib +erlotinib	Phase I/II	Patients with recurrent or metastatic EGFR-NSCLC
Hsp70
Targeted NK cell based adoptive immunotherapy	NCT02118415	Hsp70 NK cell based adoptive immunotherapy	Phase II	Patients with NSCLC after radio-chemotherapy
Hsp27
Apatorsen (OGX-427)	NCT02423590	gemcitabine/carboplatin + Apatorsen vs. gemcitabine/carboplatin	Phase II	Patients with previously untreated advanced squamous cell lung cancer